Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) who were prospectively defined as frail using a simplified version of the Comprehensive Geriatric Assessment (CGA). Patients had...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:Haematologica
প্রধান লেখক: Storti, Sergio, Spina, Michele, Pesce, Emanuela Anna, Salvi, Flavia, Merli, Michele, Ruffini, Alessia, Cabras, Giuseppina, Chiappella, Annalisa, Angelucci, Emanuele, Fabbri, Alberto, Liberati, Anna Marina, Tani, Monica, Musuraca, Gerardo, Molinari, Annalia, Petrilli, Maria Pia, Palladino, Carmela, Ciancia, Rosanna, Ferrario, Andrea, Gasbarrino, Cristiana, Monaco, Federico, Fraticelli, Vincenzo, De Vellis, Annalisa, Merli, Francesco, Luminari, Stefano
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: Ferrata Storti Foundation 2018
বিষয়গুলি:
Article
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC6068040/
https://ncbi.nlm.nih.gov/pubmed/29748444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.186569
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি